Cellectis S.A. Files 2024 Annual Report
Ticker: CLLS · Form: 20-F · Filed: Mar 14, 2025 · CIK: 1627281
Sentiment: neutral
Topics: annual-report, financials, biotech
Related Tickers: CXT
TL;DR
Cellectis 20-F filed: shows cash, lease debts, and mentions Calyxt/AstraZeneca. Check financials.
AI Summary
Cellectis S.A. filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial position, including cash and cash equivalents and lease debts. It also mentions significant agreements and equity awards, with specific references to entities like Calyxt Inc. and AstraZeneca.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Cellectis's financial health and operational status for the past fiscal year, including key assets and liabilities.
Risk Assessment
Risk Level: medium — The filing is a standard annual report, but the nature of the biotechnology industry and potential future financing needs can introduce medium-level risk.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the annual report.)
- 2025-03-14 — Filing Date (The date the 20-F was submitted to the SEC.)
Key Players & Entities
- Cellectis S.A. (company) — Filer of the 20-F report
- Calyxt Inc. (company) — Mentioned in relation to ordinary shares and equity awards
- AstraZeneca (company) — Mentioned in relation to financial data
- 2024-12-31 (date) — Fiscal year end for the report
- 2025-03-14 (date) — Filing date of the report
FAQ
What was the company's cash and cash equivalent position as of December 31, 2023?
The filing indicates 'clls:CashAndCashEquivalentMember' for '2023-12-31', suggesting this data is available within the full report.
What is the status of Cellectis's lease debts as of December 31, 2024?
The filing references 'clls:CurrentLeaseDebtsMember' for '2024-12-31', indicating current lease debts are reported.
Are there any significant agreements mentioned related to advances or refunds?
Yes, the filing mentions 'clls:GrantAndRefundableAdvanceAgreementMember' with a date of '2024-12-06'.
What is the relationship between Cellectis and Calyxt Inc. as detailed in this filing?
Calyxt Inc. is mentioned as a member ('clls:CalyxtIncMember') in relation to ordinary shares ('ifrs-full:OrdinarySharesMember') for the period '2023-01-01' to '2023-12-31'.
Does the filing provide information on equity awards granted during the fiscal year?
Yes, the filing references 'clls:EquityAwardsMember' for the period '2023-01-01' to '2023-12-31'.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 14, 2025 regarding Cellectis S.A. (CLLS).